PPTA Twitter

PlasmaProteins Your #plasmadonation can make a difference in the lives of those living with rare conditions such as #hemophilia or alpha-1 antitrypsin deficiency, both of which can be treated with #plasmaprotein therapies. Learn more about why your donation matters: bit.ly/2kx5I0P
3 days ago.
PlasmaProteins Save the Date! International Plasma Awareness Week (IPAW) is just one month away. From Oct 7-11, help us recognize plasma donors and raise awareness about the life-saving value of #plasmaprotein therapies. Learn more: bit.ly/2KuL6QT #IPAW2019 pic.twitter.com/Rg2zgY0d19
5 days ago.

The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act

PPTA is concerned that access to therapies and important protections for vulnerable patients with rare diseases will not be included in the Better Care Reconciliation Act (BCRA).  In an effort to end what they consider a failing exchange system, Senate Republicans are trying to garner enough votes to proceed to debate on repeal.

The draft versions of BCRA, with various amendments, would allow changes to the Essential Health Benefits that patients who use plasma protein therapies rely on. These include:

1. Prohibit lifetime and annual caps on coverage
2. Prohibit being denied coverage because of a pre-existing condition
3. Allow dependent children on their parents’ insurance until age 26
4. Limit maximum out of pocket costs for patients

Since access to plasma protein therapies to treat primary immunodeficiencies, alpha-1 antitrypsin deficiency, hereditary angioedema and bleeding disorders, such as hemophilia, is so vital to patient well-being, PPTA is telling Senators to vote NO on the current motion to proceed. The four patient protections must be included in whatever health care legislation moves forward in Congress.

 July 25, 2017

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100